The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal disease

Detalhes bibliográficos
Autor(a) principal: Pereira,Luísa H.
Data de Publicação: 2019
Outros Autores: Mendes,Filipa, Fragoso,André, Silva,Ana P., Neves,Pedro L.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400005
Resumo: Introduction: Renal replacement therapy has not always been shown to benefit end-stage renal failure patients who are elderly or have multiple comorbidities. The Charlson Comorbidity Index (CCI) predicts mortality and is frequently used for risk stratification in clinical practice. We evaluated correlation between the Charlson Comorbidity Index and hospital admissions and mortality in chronic kidney disease patients. Methods: This retrospective observational study included 693 patients with an estimated glomerular filtration rate (eGFR)<30 ml/min/1.73m2, followed in pre-dialysis medical appointments (2008-2012). Based on the CCI, the subjects were collapsed into 4 risk groups: <25th percentile (CCI≤5.2; n=172) - G1; 25-50th percentile (CCI: 5.3-6.4; n=162) - G2; 50-75th percentile (CCI: 6.5-7.4; n=177) - G3; and &gt;75th percentile (CCI≥7.5; n=182) - G4. Descriptive statistics, ANOVA, the chi-square and the log-rank tests were used for comparison between groups. The Bonferroni test was used as a post-hoc test. Kaplan-Meier analysis was used to evaluate mortality. Results: Mean age was 70.1 years, 54% women, with an eGFR of 20.2±9.2 ml/min (Modification of Diet in Renal Disease). G1 patients were younger (p<0.001) and showed higher hemoglobin (p<0.001), eGFR (p=0.025), calcium (p=0.033) and albumin (p<0.001). In a multivariate logistic regression model adjusted for gender, age, hemoglobin, phosphorus, parathormone, eGFR, albumin and blood pressure, CCI is a risk factor for hospitalization (ORa=1.362, Cl 95% 1.175-1.580, p<0.0001). Multivariate Cox regression analysis identified higher scores of CCI as an independent risk factor for cardiovascular mortality (HRa=1.24, Cl 95% 1.053-1.467, p=0.010). Survival at 85 months was progressively shorter with higher CCI (G1=86.7%, G2=65.9%, G3=59.35 % and G4=30.4%, log-rank=34.465, p=0.0001). Conclusion: The Charlson Comorbidity Index was shown to be a strong predictor of mortality and hospitalizations in patients with stage IV chronic kidney disease. It might be a valuable tool in dialysis decision-making for patients with advanced chronic kidney disease and severe comorbidity burden.
id RCAP_999b48b1ad23f7c1c2137d4241c099ec
oai_identifier_str oai:scielo:S0872-01692019000400005
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal diseaseCharlson Comorbidity IndexChronic Kidney DiseaseComorbiditiesElderlySurvivalIntroduction: Renal replacement therapy has not always been shown to benefit end-stage renal failure patients who are elderly or have multiple comorbidities. The Charlson Comorbidity Index (CCI) predicts mortality and is frequently used for risk stratification in clinical practice. We evaluated correlation between the Charlson Comorbidity Index and hospital admissions and mortality in chronic kidney disease patients. Methods: This retrospective observational study included 693 patients with an estimated glomerular filtration rate (eGFR)<30 ml/min/1.73m2, followed in pre-dialysis medical appointments (2008-2012). Based on the CCI, the subjects were collapsed into 4 risk groups: <25th percentile (CCI≤5.2; n=172) - G1; 25-50th percentile (CCI: 5.3-6.4; n=162) - G2; 50-75th percentile (CCI: 6.5-7.4; n=177) - G3; and &gt;75th percentile (CCI≥7.5; n=182) - G4. Descriptive statistics, ANOVA, the chi-square and the log-rank tests were used for comparison between groups. The Bonferroni test was used as a post-hoc test. Kaplan-Meier analysis was used to evaluate mortality. Results: Mean age was 70.1 years, 54% women, with an eGFR of 20.2±9.2 ml/min (Modification of Diet in Renal Disease). G1 patients were younger (p<0.001) and showed higher hemoglobin (p<0.001), eGFR (p=0.025), calcium (p=0.033) and albumin (p<0.001). In a multivariate logistic regression model adjusted for gender, age, hemoglobin, phosphorus, parathormone, eGFR, albumin and blood pressure, CCI is a risk factor for hospitalization (ORa=1.362, Cl 95% 1.175-1.580, p<0.0001). Multivariate Cox regression analysis identified higher scores of CCI as an independent risk factor for cardiovascular mortality (HRa=1.24, Cl 95% 1.053-1.467, p=0.010). Survival at 85 months was progressively shorter with higher CCI (G1=86.7%, G2=65.9%, G3=59.35 % and G4=30.4%, log-rank=34.465, p=0.0001). Conclusion: The Charlson Comorbidity Index was shown to be a strong predictor of mortality and hospitalizations in patients with stage IV chronic kidney disease. It might be a valuable tool in dialysis decision-making for patients with advanced chronic kidney disease and severe comorbidity burden.Sociedade Portuguesa de Nefrologia2019-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400005Portuguese Journal of Nephrology &amp; Hypertension v.33 n.4 2019reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400005Pereira,Luísa H.Mendes,FilipaFragoso,AndréSilva,Ana P.Neves,Pedro L.info:eu-repo/semantics/openAccess2024-02-06T17:05:04Zoai:scielo:S0872-01692019000400005Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:19:03.015257Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal disease
title The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal disease
spellingShingle The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal disease
Pereira,Luísa H.
Charlson Comorbidity Index
Chronic Kidney Disease
Comorbidities
Elderly
Survival
title_short The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal disease
title_full The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal disease
title_fullStr The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal disease
title_full_unstemmed The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal disease
title_sort The Charlson Comorbidity Index - its impact on hospitalization and mortality in chronic renal disease
author Pereira,Luísa H.
author_facet Pereira,Luísa H.
Mendes,Filipa
Fragoso,André
Silva,Ana P.
Neves,Pedro L.
author_role author
author2 Mendes,Filipa
Fragoso,André
Silva,Ana P.
Neves,Pedro L.
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Pereira,Luísa H.
Mendes,Filipa
Fragoso,André
Silva,Ana P.
Neves,Pedro L.
dc.subject.por.fl_str_mv Charlson Comorbidity Index
Chronic Kidney Disease
Comorbidities
Elderly
Survival
topic Charlson Comorbidity Index
Chronic Kidney Disease
Comorbidities
Elderly
Survival
description Introduction: Renal replacement therapy has not always been shown to benefit end-stage renal failure patients who are elderly or have multiple comorbidities. The Charlson Comorbidity Index (CCI) predicts mortality and is frequently used for risk stratification in clinical practice. We evaluated correlation between the Charlson Comorbidity Index and hospital admissions and mortality in chronic kidney disease patients. Methods: This retrospective observational study included 693 patients with an estimated glomerular filtration rate (eGFR)<30 ml/min/1.73m2, followed in pre-dialysis medical appointments (2008-2012). Based on the CCI, the subjects were collapsed into 4 risk groups: <25th percentile (CCI≤5.2; n=172) - G1; 25-50th percentile (CCI: 5.3-6.4; n=162) - G2; 50-75th percentile (CCI: 6.5-7.4; n=177) - G3; and &gt;75th percentile (CCI≥7.5; n=182) - G4. Descriptive statistics, ANOVA, the chi-square and the log-rank tests were used for comparison between groups. The Bonferroni test was used as a post-hoc test. Kaplan-Meier analysis was used to evaluate mortality. Results: Mean age was 70.1 years, 54% women, with an eGFR of 20.2±9.2 ml/min (Modification of Diet in Renal Disease). G1 patients were younger (p<0.001) and showed higher hemoglobin (p<0.001), eGFR (p=0.025), calcium (p=0.033) and albumin (p<0.001). In a multivariate logistic regression model adjusted for gender, age, hemoglobin, phosphorus, parathormone, eGFR, albumin and blood pressure, CCI is a risk factor for hospitalization (ORa=1.362, Cl 95% 1.175-1.580, p<0.0001). Multivariate Cox regression analysis identified higher scores of CCI as an independent risk factor for cardiovascular mortality (HRa=1.24, Cl 95% 1.053-1.467, p=0.010). Survival at 85 months was progressively shorter with higher CCI (G1=86.7%, G2=65.9%, G3=59.35 % and G4=30.4%, log-rank=34.465, p=0.0001). Conclusion: The Charlson Comorbidity Index was shown to be a strong predictor of mortality and hospitalizations in patients with stage IV chronic kidney disease. It might be a valuable tool in dialysis decision-making for patients with advanced chronic kidney disease and severe comorbidity burden.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400005
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692019000400005
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Nefrologia
publisher.none.fl_str_mv Sociedade Portuguesa de Nefrologia
dc.source.none.fl_str_mv Portuguese Journal of Nephrology &amp; Hypertension v.33 n.4 2019
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137280187695104